The Elsevier Office of Continuing Medical Education and In Vivo Academy Limited appreciate your opinions to help assist us in the evaluation of the effectiveness of this activity and to identify your ongoing educational needs.

Please complete this evaluation form. You must complete this evaluation form to receive acknowledgement for completing this activity.

*
*
*
*
*
*
*
*
PoorFairGoodVery goodExcellent
Explain the modes of action of available immunotherapies for treating metastatic melanoma
Outline the rationale for the use of immune checkpoint inhibitors singly or in combination
Discuss the evidence (clinical trial data) for the efficacy of immune checkpoint inhibitors in metastatic melanoma
List immune-related adverse events (irAEs) that may occur with the use of immune checkpoint inhibitors and how they should be identified and managed.
*
NeverRarelySometimesMost of the timeAlwaysN/A
Consider prescribing cancer immunotherapy for treating metastatic melanoma
Apply published detailed management guideline in managing and treating the most common irAEs
*
NeverRarelySometimesMost of the timeAlwaysN/A
Consider prescribing cancer immunotherapy for treating metastatic melanoma
Apply published detailed management guideline in managing and treating the most common irAEs
*
Strongly disagreeDisagreeNeutralAgreeStrongly agree
The information presented was without promotional or commercial bias
The content provided a fair and balanced coverage of the topic
Was scientifically rigorous and evidence based
Provided appropriate and effective opportunities for active learning (e.g., discussion, Q&A)
Promoted improvements or quality in health care
The information provided with regard to faculty financial relationships met my needs for disclosure
The speakers were knowledgeable and presented the information clearly
The format of the discussion was relevant and enhanced my knowledge of the subject
*
PoorFairGoodVery goodExcellent
Professor Grant McArthur
Dr Matteo Carlino
*
*

Attestation to time spent on activity:

The Elsevier Office of Continuing Medical Education designates this live activity for a maxiumum of 1.0AMA PRA Category 1 CreditTM.

*